GlycoVaxyn, GSK in deal for bacterial vaccines

GlycoVaxyn AG (Schlieren, Switzerland) partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to use GlycoVaxyn's bio-conjugation technology to develop new bacterial vaccines against an undisclosed se...